Immunic, Inc. (IMUX) is expected to report a consensus EPS of -$1.24 on zero revenue, with the current stock price of $14.05 trading significantly below the $47.57 average analyst price target.
Investors are primarily focused on the clinical development timeline for the lead asset vidofludimus calcium (IMU-838) and the company’s cash runway following a recent $200 million private placement.
The Phase 3 ENSURE trials in relapsing multiple sclerosis remain the central value driver, with top-line data anticipated by the end of 2026. Management is also expected to provide updates on the Phase 2 CALLIPER trial in progressive MS and early-stage IMU-856 development programs.